152 related articles for article (PubMed ID: 22257480)
1. Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study.
DU YQ; Guo WY; Zou DW; Zhan XB; Li Z; Hu JH; Gong YF; He J; Lu JP; Li ZS
J Dig Dis; 2012 Feb; 13(2):113-9. PubMed ID: 22257480
[TBL] [Abstract][Full Text] [Related]
2. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial.
Wang L; Zhou L; Hu H; Lin S; Xia J
Curr Med Res Opin; 2012 Jan; 28(1):101-9. PubMed ID: 22070512
[TBL] [Abstract][Full Text] [Related]
3. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
[TBL] [Abstract][Full Text] [Related]
6. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
Cho H; Choi MK; Cho DY; Yeo CW; Jeong HE; Shon JH; Lee JY; Shin JS; Cho M; Kim DY; Shin JG
J Clin Pharmacol; 2012 Jul; 52(7):976-84. PubMed ID: 21593280
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the effect of ilaprazole on intragastric pH in patients with duodenal ulcer].
Zhou LY; Lin SR; Yang YS; Zhang ST; Yuan YZ; Shi RH; Hou XH; Xia JL; Hu HT; Qin XH
Zhonghua Nei Ke Za Zhi; 2010 Apr; 49(4):290-2. PubMed ID: 20627032
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
[TBL] [Abstract][Full Text] [Related]
10. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
11. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
12. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
Wang H; Nie YQ; Dai SJ; She QZ; Li YY
Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
[TBL] [Abstract][Full Text] [Related]
13. [Dosaging of proton pumps inhibitors].
Brørs O
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2397-9. PubMed ID: 16998554
[No Abstract] [Full Text] [Related]
14. Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers.
Ho KY; Kuan A; Zaño F; Goh KL; Mahachai V; Kim DY; Yoon HM
J Gastroenterol; 2009; 44(7):697-707. PubMed ID: 19434360
[TBL] [Abstract][Full Text] [Related]
15. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
Hartmann M; Theiss U; Huber R; Lühmann R; Bliesath H; Wurst W; Lücker PW
Aliment Pharmacol Ther; 1996 Jun; 10(3):359-66. PubMed ID: 8791964
[TBL] [Abstract][Full Text] [Related]
16. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.
Furuta K; Adachi K; Ohara S; Morita T; Tanimura T; Koshino K; Kinoshita Y
J Int Med Res; 2010; 38(4):1473-83. PubMed ID: 20926021
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.
Tutuian R; Katz PO; Bochenek W; Castell DO
Aliment Pharmacol Ther; 2002 Apr; 16(4):829-36. PubMed ID: 11929403
[TBL] [Abstract][Full Text] [Related]
19. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Tazuma S; Horikawa Y; Nakamura M
Dig Dis Sci; 2005 Jul; 50(7):1202-6. PubMed ID: 16047460
[TBL] [Abstract][Full Text] [Related]
20. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]